<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2022-2-18-25</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-1780</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИ</subject></subj-group></article-categories><title-group><article-title>Association between redox imbalance, pterin metabolism markers, and early extrapyramidal side effects of antipsychotics in schizophrenia: pilot study</article-title><trans-title-group xml:lang="ru"><trans-title>Пилотное исследование связи окислительно-восстановительного дисбаланса, маркеров метаболизма птеринов и ранних экстрапирамидных побочных эффектов антипсихотиков при шизофрении</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6155-1007</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жиляева</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhilyaeva</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Татьяна Владимировна Жиляева</p><p>Россия, 603005, Нижний Новгород, пл. Минина и Пожарского, 10/1</p><p>Россия, 192019, Санкт-Петербург, ул. Бехтерева, 3</p></bio><bio xml:lang="en"><p>Tatiana Vladimirovna Zhilyaeva</p><p>10/1, Minin and Pozharsky Sq., Nizhny Novgorod 603005, Russia</p><p>3, Bekhterev St., Saint Petersburg 192019, Russia</p></bio><email xlink:type="simple">bizet@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2259-0908</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Швачкина</surname><given-names>Д. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Shvachkina</surname><given-names>D. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 603005, Нижний Новгород, пл. Минина и Пожарского, 10/1</p></bio><bio xml:lang="en"><p>10/1, Minin and Pozharsky Sq., Nizhny Novgorod 603005, Russia</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8932-7418</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пятойкина</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Piatoikina</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 603155, Нижний Новгород, ул. Ульянова, 41</p></bio><bio xml:lang="en"><p>41, Ulianova St., Nizhny Novgorod 603155, Russia</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9016-2390</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жукова</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhukova</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 603105, Нижний Новгород, ул. Семашко, 20</p></bio><bio xml:lang="en"><p>20, Semashko St., Nizhny Novgorod 603105, Russia</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7529-2544</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Костина</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kostina</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 603005, Нижний Новгород, пл. Минина и Пожарского, 10/1</p></bio><bio xml:lang="en"><p>10/1, Minin and Pozharsky Sq., Nizhny Novgorod 603005, Russia</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1144-8006</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щербатюк</surname><given-names>Т. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Shcherbatyuk</surname><given-names>T. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 603105, Нижний Новгород, ул. Семашко, 20</p><p>Россия, 142290, Московская обл., Пущино, проспект Науки, 3</p></bio><bio xml:lang="en"><p>20, Semashko St., Nizhny Novgorod 603105, Russia</p><p>3, Nauki Prosp., Pushchino 142290, Moscow region, Russia</p></bio><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7910-9129</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мазо</surname><given-names>Г. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Mazo</surname><given-names>G. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 142290, Московская обл., Пущино, проспект Науки, 3</p></bio><bio xml:lang="en"><p>3, Nauki Prosp., Pushchino 142290, Moscow region, Russia</p></bio><xref ref-type="aff" rid="aff-6"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава России; ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Privolzhsky Research Medical University, Ministry of Health of Russia; V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Privolzhsky Research Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ГБУЗ НО «Клиническая психиатрическая больница №1 города Нижнего Новгорода»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Nizhny Novgorod City Clinical Psychiatric Hospital №1</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФБУН «Нижегородский научно-исследовательский институт гигиены и профпатологии» Роспотребнадзора</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Nizhny Novgorod Research Institute for Hygiene and Occupational&#13;
Pathology, Rospotrebnadzor</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>ФБУН «Нижегородский научно-исследовательский институт гигиены и профпатологии» Роспотребнадзора; ФГБОУ ВО «Пущинский государственный естественно-научный институт»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Nizhny Novgorod Research Institute for Hygiene and Occupational&#13;
Pathology, Rospotrebnadzor; Pushchino State Institute of Natural Science</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="ru"><institution>ФГБОУ ВО «Пущинский государственный естественно-научный институт»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pushchino State Institute of Natural Science</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>17</day><month>04</month><year>2022</year></pub-date><volume>14</volume><issue>2</issue><fpage>18</fpage><lpage>25</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Zhilyaeva T.V., Shvachkina D.S., Piatoikina A.S., Zhukova E.S., Kostina O.V., Shcherbatyuk T.G., Mazo G.E., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Жиляева Т.В., Швачкина Д.С., Пятойкина А.С., Жукова Е.С., Костина О.В., Щербатюк Т.Г., Мазо Г.Э.</copyright-holder><copyright-holder xml:lang="en">Zhilyaeva T.V., Shvachkina D.S., Piatoikina A.S., Zhukova E.S., Kostina O.V., Shcherbatyuk T.G., Mazo G.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/1780">https://nnp.ima-press.net/nnp/article/view/1780</self-uri><abstract><p>Antipsychotics (AP) administration in schizophrenia patients is associated with several side effects (SE), in particular, with extrapyramidal (EP). Data suggests that oxidative damage to dopaminergic neurons in the EP system may be related to tardive dyskinesia and Parkinson's disease (PD) development, although data on the role of oxidative stress in the development of early EPSE of AP is lacking. Another poorly studied hypothesis of the EP-symptoms pathogenesis considers disorders of folate (pterin) metabolism.</p><sec><title>Objective</title><p>Objective: to evaluate the relationship between redox imbalance and pterin metabolism with the severity of early EPSE caused by AP used in the schizophrenia treatment.</p></sec><sec><title>Patients and methods</title><p>Patients and methods. The study included 50 patients with the first episode of schizophrenia. EP symptoms were evaluated using the UKU Side-Effect Rating Scale (“UKU-SERS-Clin” version). The levels of reduced glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), malondialdehyde (MDA), aldehyde-2,4-dinitrophenylhydrazone, ketone-2,4-dinitrophenylhydrazone were assessed in blood plasma; levels of BH4, folate, cobalamin (vitamin B12), and homocysteine – in blood serum; superoxide dismutase (SOD) and catalase activity – in erythrocytes.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. EPSE severity was inversely proportional inversely proportional to the GSH level and directly proportional to the SOD activity. EPSE severity was also associated with AP selectivity, but not with their dosages. However, AP selectivity was not associated with studied biochemical parameters. MDA level in patients prescribed with amantadine was lower than in other participants.</p></sec><sec><title>Conclusion</title><p>Conclusion. Early AP-induced EPSE were associated with redox imbalance, which indicates the necessity for further research aiming at prevention of secondary neurodegenerative diseases in patients with schizophrenia receiving AP.</p></sec></abstract><trans-abstract xml:lang="ru"><p>Применение антипсихотических средств (АП) в лечении шизофрении связано с различными побочными эффектами (ПЭ), в частности, экстрапирамидными (ЭП). Имеются данные о том, что окислительное повреждение дофаминергических нейронов в ЭП-системе может приводить к развитию поздней дискинезии и болезни Паркинсона, но сведений о роли оксидативного стресса в развитии ранних ЭППЭ, возникающих на фоне терапии АП, в литературе не встречается. Другая малоизученная гипотеза патогенеза ЭП-симптомов рассматривает нарушения обмена фолатов (птеринов).</p><p>Цель исследования – предварительная оценка связи окислительно-восстановительного дисбаланса и метаболизма птеринов с выраженностью ранних ЭППЭ, вызванных применяемыми при лечении шизофрении АП.</p><sec><title>Пациенты и методы</title><p>Пациенты и методы. В исследование включены 50 пациентов с первым эпизодом шизофрении. Оценка ЭП-симптомов проводилась с помощью Шкалы для оценки побочных эффектов UKU (UKU Side-Effect Rating Scale; версия UKUSERS-Clin). Уровни восстановленного глутатиона (GSH), малонового диальдегида (МДА), альдегид-2,4-динитрофенилгидразонов, кетон-2,4-динитрофенилгидразонов оценивали в плазме крови; уровни BH4, фолатов, кобаламина (витамин B12) и гомоцистеина – в сыворотке крови; активность супероксиддисмутазы (СОД) и каталазы – в эритроцитах.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Обнаружено, что тяжесть ЭППЭ обратно пропорциональна уровню GSH и прямо пропорциональна активности СОД. Выраженность ЭППЭ также была связана с селективностью АП, но не с их дозами. Однако селективность АП не влияла на изучаемые биохимические показатели. У пациентов, получавших амантадин, уровень МДА был ниже, чем у других пациентов.</p></sec><sec><title>Заключение</title><p>Заключение. Выявлена ассоциация ранних ЭППЭ, вызванных АП, с окислительно-восстановительным дисбалансом, что указывает на необходимость дальнейших исследований с целью разработки стратегий профилактики вторичных нейродегенеративных расстройств при шизофрении у пациентов, получающих АП.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>нейролептики</kwd><kwd>экстрапирамидные побочные эффекты</kwd><kwd>окислительный стресс</kwd><kwd>метаболизм птеринов</kwd></kwd-group><kwd-group xml:lang="en"><kwd>antipsychotics</kwd><kwd>extrapyramidal side effects</kwd><kwd>oxidative stress</kwd><kwd>pterin metabolism</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование биохимических маркеров поддержано РФФИ (грант № 19-015-00420 А; грант № 20-20-015-00301)</funding-statement><funding-statement xml:lang="en">The study of biochemical markers was supported by the Russian Foundation for Basic Research (grant № 19-015-00420 А; grant № 20-20-015-00301)</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Potkin SG, Kane JM, Correll CU, et al. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr. 2020 Jan 7;6(1):1. doi: 10.1038/s41537-019-0090-z</mixed-citation><mixed-citation xml:lang="en">Potkin SG, Kane JM, Correll CU, et al. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr. 2020 Jan 7;6(1):1. doi: 10.1038/s41537-019-0090-z</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Saddichha S, Kumar R, Babu GN, Chandra P. Aripiprazole Associated With Acute Dystonia, Akathisia, and Parkinsonism in a Single Patient. J Clin Pharmacol. 2012 Sep;52(9):1448-9. doi: 10.1177/0091270011414573. Epub 2011 Sep 8.</mixed-citation><mixed-citation xml:lang="en">Saddichha S, Kumar R, Babu GN, Chandra P. Aripiprazole Associated With Acute Dystonia, Akathisia, and Parkinsonism in a Single Patient. J Clin Pharmacol. 2012 Sep;52(9):1448-9. doi: 10.1177/0091270011414573. Epub 2011 Sep 8.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Caroff SN, Campbell EC. Drug-Induced Extrapyramidal Syndromes: Implications for Contemporary Practice. Psychiatr Clin North Am. 2016 Sep;39(3):391-411. doi: 10.1016/j.psc.2016.04.003. Epub 2016 Jun 23.</mixed-citation><mixed-citation xml:lang="en">Caroff SN, Campbell EC. Drug-Induced Extrapyramidal Syndromes: Implications for Contemporary Practice. Psychiatr Clin North Am. 2016 Sep;39(3):391-411. doi: 10.1016/j.psc.2016.04.003. Epub 2016 Jun 23.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Druschky K, Bleich S, Grohmann R, et al. Severe parkinsonism under treatment with antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci. 2020 Feb;270(1):35-47. doi: 10.1007/s00406-019-01060-7. Epub 2019 Aug 23.</mixed-citation><mixed-citation xml:lang="en">Druschky K, Bleich S, Grohmann R, et al. Severe parkinsonism under treatment with antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci. 2020 Feb;270(1):35-47. doi: 10.1007/s00406-019-01060-7. Epub 2019 Aug 23.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Федорова НВ, Ветохина ТН. Диагностика и лечение нейролептических экстрапирамидных синдромов: Учебно-методическое пособие. Москва: РМАПО; 2006.</mixed-citation><mixed-citation xml:lang="en">Fedorova NV, Vetokhina TN. Diagnostika i lecheniye neyrolepticheskikh ekstrapiramidnykh sindromov: Uchebno-metodicheskoye posobiye [Diagnostics and treatment of neuroleptic extrapyramidal syndromes: Teaching aid]. Moscow: RMAPO; 2006 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Shireen E. Experimental treatment of antipsychotic-induced movement disorders. J Exp Pharmacol. 2016 Aug 8;8:1-10. doi: 10.2147/JEP.S63553</mixed-citation><mixed-citation xml:lang="en">Shireen E. Experimental treatment of antipsychotic-induced movement disorders. J Exp Pharmacol. 2016 Aug 8;8:1-10. doi: 10.2147/JEP.S63553</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Chen X, Guo C, Kong J. Oxidative stress in neurodegenerative diseases. Neural Regen Res. 2012 Feb 15;7(5):376-85. doi: 10.3969/j.issn.1673-5374.2012.05.009</mixed-citation><mixed-citation xml:lang="en">Chen X, Guo C, Kong J. Oxidative stress in neurodegenerative diseases. Neural Regen Res. 2012 Feb 15;7(5):376-85. doi: 10.3969/j.issn.1673-5374.2012.05.009</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ward KM, Citrome L. Antipsychotic- Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management. Neurol Ther. 2018 Dec;7(2):233-48. doi: 10.1007/s40120-018-0105-0. Epub 2018 Jul 19.</mixed-citation><mixed-citation xml:lang="en">Ward KM, Citrome L. Antipsychotic- Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management. Neurol Ther. 2018 Dec;7(2):233-48. doi: 10.1007/s40120-018-0105-0. Epub 2018 Jul 19.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wu YL, Ding XX, Sun YH, et al. Methylenetetrahydrofolate reductase (MTHFR) C677T/A1298C polymorphisms and susceptibility to Parkinson's disease: a meta-analysis. J Neurol Sci. 2013 Dec 15;335(1-2):14-21. doi: 10.1016/j.jns.2013.09.006. Epub 2013 Sep 12.</mixed-citation><mixed-citation xml:lang="en">Wu YL, Ding XX, Sun YH, et al. Methylenetetrahydrofolate reductase (MTHFR) C677T/A1298C polymorphisms and susceptibility to Parkinson's disease: a meta-analysis. J Neurol Sci. 2013 Dec 15;335(1-2):14-21. doi: 10.1016/j.jns.2013.09.006. Epub 2013 Sep 12.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Жиляева ТВ, Акимова ЕВ, Благонравова АС, Мазо ГЭ. Взаимодействие генов ферментов фолатного цикла и риск развития экстрапирамидных побочных эффектов антипсихотиков. Неврология, нейропсихиатрия, психосоматика. 2020;12(6):54-60. doi: 10.14412/2074-2711-2020-6-54-60</mixed-citation><mixed-citation xml:lang="en">Zhilyaeva TV, Akimova EV, Blagonravova AS, Mazo GE. The interaction of folate cycle enzyme genes and the risk of extrapyramidal side effects of antipsychotics. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(6):54-60. doi: 10.14412/2074-2711-2020-6-54-60 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Atmaca G. Antioxidant effects of sulfurcontaining amino acids. Yonsei Med J. 2004 Oct 31;45(5):776-88. doi: 10.3349/ymj.2004.45.5.776</mixed-citation><mixed-citation xml:lang="en">Atmaca G. Antioxidant effects of sulfurcontaining amino acids. Yonsei Med J. 2004 Oct 31;45(5):776-88. doi: 10.3349/ymj.2004.45.5.776</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Dietrich-Muszalska A, Malinowska J, Olas B, et al. The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients. Neurochem Res. 2012 May;37(5):1057-62. doi: 10.1007/s11064-012-0707-3. Epub 2012 Jan 24.</mixed-citation><mixed-citation xml:lang="en">Dietrich-Muszalska A, Malinowska J, Olas B, et al. The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients. Neurochem Res. 2012 May;37(5):1057-62. doi: 10.1007/s11064-012-0707-3. Epub 2012 Jan 24.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Goff DC, Bottiglieri T, Arning E, et al. Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry. 2004 Sep;161(9):1705-8. doi: 10.1176/appi.ajp.161.9.1705</mixed-citation><mixed-citation xml:lang="en">Goff DC, Bottiglieri T, Arning E, et al. Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry. 2004 Sep;161(9):1705-8. doi: 10.1176/appi.ajp.161.9.1705</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Moore AP, Behan PO, Jacobson W, Armarego WL. Biopterin in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1987 Jan;50(1):85-7. doi: 10.1136/jnnp.50.1.85</mixed-citation><mixed-citation xml:lang="en">Moore AP, Behan PO, Jacobson W, Armarego WL. Biopterin in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1987 Jan;50(1):85-7. doi: 10.1136/jnnp.50.1.85</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Van Strien AM, Keijsers CJ, Derijks HJ, van Marum RJ. Rating scales to measure side effects of antipsychotic medication: A systematic review. J Psychopharmacol. 2015 Aug;29(8):857-66. doi: 10.1177/0269881115593893. Epub 2015 Jul 8.</mixed-citation><mixed-citation xml:lang="en">Van Strien AM, Keijsers CJ, Derijks HJ, van Marum RJ. Rating scales to measure side effects of antipsychotic medication: A systematic review. J Psychopharmacol. 2015 Aug;29(8):857-66. doi: 10.1177/0269881115593893. Epub 2015 Jul 8.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957 May;226(1):497-509.</mixed-citation><mixed-citation xml:lang="en">Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957 May;226(1):497-509.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Levine RL, Garland D, Oliver CN, et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990;186:464-78. doi: 10.1016/0076-6879(90)86141-h</mixed-citation><mixed-citation xml:lang="en">Levine RL, Garland D, Oliver CN, et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990;186:464-78. doi: 10.1016/0076-6879(90)86141-h</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Дубинина ЕЕ, Бурмистров СО, Ходов ДА, Поротов ИГ. Окислительная модификация белков сыворотки крови человека, метод ее определения. Вопросы медицинской химии. 1995;41(1):24-6.</mixed-citation><mixed-citation xml:lang="en">Dubinina EE, Burmistrov SO, Khodov DA, Porotov IG. Oxidative modification of human serum proteins. A method of determining it. Voprosy meditsinskoi khimii. 1995 Jan-Feb;41(1):24-6 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Либин ЛЯ, Иванов МВ, Ещенко НД и др. К вопросу изучения механизмов развития оксидативного стресса у больных параноидной приступообразной шизофренией, получающих антипсихотическую терапию. Психиатрия и психофармакотерапия. 2012;14(5):19-25.</mixed-citation><mixed-citation xml:lang="en">Libin LYa, Ivanov MV, Eshchenko ND, et al. On the study of the mechanisms of oxidative stress in patients with paranoid schizophrenia paroxysmal receiving antipsychotic medication. Psihiatriya i psihofarmakoterapiya. 2012;14(5):19-25 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Danivas V, Venkatasubramanian G. Current perspectives on chlorpromazine equivalents: Comparing apples and oranges! Indian J Psychiatry. 2013 Apr;55(2):207-8. doi: 10.4103/0019-5545.111475</mixed-citation><mixed-citation xml:lang="en">Danivas V, Venkatasubramanian G. Current perspectives on chlorpromazine equivalents: Comparing apples and oranges! Indian J Psychiatry. 2013 Apr;55(2):207-8. doi: 10.4103/0019-5545.111475</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ermakov EA, Dmitrieva EM, Parshukova DA, et al. Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives. Oxid Med Cell Longev. 2021 Jan 23;2021:8881770. doi: 10.1155/2021/8881770</mixed-citation><mixed-citation xml:lang="en">Ermakov EA, Dmitrieva EM, Parshukova DA, et al. Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives. Oxid Med Cell Longev. 2021 Jan 23;2021:8881770. doi: 10.1155/2021/8881770</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ooi SL, Green R, Pak SC. N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence. Biomed Res Int. 2018 Oct 22;2018:2469486. doi: 10.1155/2018/2469486</mixed-citation><mixed-citation xml:lang="en">Ooi SL, Green R, Pak SC. N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence. Biomed Res Int. 2018 Oct 22;2018:2469486. doi: 10.1155/2018/2469486</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Bardgett ME, Wrona CT, Newcomer JW, Csernansky JG. Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics. Eur J Pharmacol. 1993 Jan 19;230(3):245-50. doi: 10.1016/0014-2999(93)90557-x</mixed-citation><mixed-citation xml:lang="en">Bardgett ME, Wrona CT, Newcomer JW, Csernansky JG. Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics. Eur J Pharmacol. 1993 Jan 19;230(3):245-50. doi: 10.1016/0014-2999(93)90557-x</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Либин ЛЯ, Дагаев СГ, Кубарская ЛГ, Ещенко НД. Влияние нейромедиаторных нарушений на перекисное окисление липидов и активность супероксиддисмутазы в коре, стриатуме и гиппокампе крыс. Вестник Санкт-Петербургского университета. Сер. 3. 2012;(3):98-105.</mixed-citation><mixed-citation xml:lang="en">Libin LYa, Dagaev SG, Kubarskaja LG, Eschenko ND. The effects of disturbance in neuromediator systems on lipid peroxidation and superoxide dismutase activity in rat brain cortex, hippocampus and striatum. Vestnik Sankt-Petersburgskogo universiteta. Ser. 3. 2012;(3):98-105 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Zhilyaeva TV, Piatoikina AS, Bavrina AP, et al. Homocysteine in Schizophrenia: Independent Pathogenetic Factor with Prooxidant Activity or Integral Marker of Other Biochemical Disturbances? Schizophr Res Treatment. 2021 Oct 13;2021:7721760. doi: 10.1155/2021/7721760</mixed-citation><mixed-citation xml:lang="en">Zhilyaeva TV, Piatoikina AS, Bavrina AP, et al. Homocysteine in Schizophrenia: Independent Pathogenetic Factor with Prooxidant Activity or Integral Marker of Other Biochemical Disturbances? Schizophr Res Treatment. 2021 Oct 13;2021:7721760. doi: 10.1155/2021/7721760</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Harris ED. Regulation of antioxidant enzymes. J Nutr. 1992 Mar;122(3 Suppl):625-6. doi: 10.1093/jn/122.suppl_3.625</mixed-citation><mixed-citation xml:lang="en">Harris ED. Regulation of antioxidant enzymes. J Nutr. 1992 Mar;122(3 Suppl):625-6. doi: 10.1093/jn/122.suppl_3.625</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Fitzmaurice PS, Tong J, Yazdanpanah M, et al. Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine. J Pharmacol Exp Ther. 2006 Nov;319(2):703-9. doi: 10.1124/jpet.106.109173. Epub 2006 Jul 20.</mixed-citation><mixed-citation xml:lang="en">Fitzmaurice PS, Tong J, Yazdanpanah M, et al. Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine. J Pharmacol Exp Ther. 2006 Nov;319(2):703-9. doi: 10.1124/jpet.106.109173. Epub 2006 Jul 20.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Узбеков МГ. Перекисное окисление липидов и антиоксидантные системы при психических заболеваниях. Сообщение II. Социальная и клиническая психиатрия. 2015;25(4):92-101.</mixed-citation><mixed-citation xml:lang="en">Uzbekov MG. Lipid peroxidation and antioxidant systems in mental illness. Message II. Social'naya i klinicheskaya psihiatriya. 2015;25(4):92-101 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Semennov IV, Zhilyaeva TV, Kasyanov ED, et al. Association of tetrahydrobiopterin deficiency with disturbances in one-carbon metabolism in patients with schizophrenia. Schizophr Res. 2021 Mar;229:132-3. doi: 10.1016/j.schres.2020.11.023. Epub 2020 Nov 21.</mixed-citation><mixed-citation xml:lang="en">Semennov IV, Zhilyaeva TV, Kasyanov ED, et al. Association of tetrahydrobiopterin deficiency with disturbances in one-carbon metabolism in patients with schizophrenia. Schizophr Res. 2021 Mar;229:132-3. doi: 10.1016/j.schres.2020.11.023. Epub 2020 Nov 21.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
